ATG-010 + ATG-008

ATG-010 + ATG-008 is a combination investigational therapy consisting of two oral small-molecule inhibitors: ATG-010 (selinexor), a first-in-class, selective inhibitor of nuclear export (SINE) targeting exportin 1 (XPO1), and ATG-008 (onatasertib), an oral dual inhibitor of mTORC1/2 kinases. - ATG-010 acts by blocking the nuclear export of tumor suppressor and regulatory proteins, resulting in their accumulation in the nucleus and promoting apoptosis of cancer cells. - ATG-008 inhibits mTORC1/2 in the PI3K/AKT/mTOR signaling pathway, leading to reduced tumor cell proliferation and survival. Preclinical studies have demonstrated that this combination leads to synergistic anti-tumor effects, particularly in triple-hit diffuse large B-cell lymphoma (DLBCL), with enhanced inhibition of tumor growth compared to single agents. Clinical trials are underway to further assess efficacy and safety in relapsed or refractory DLBCL and other malignancies[1][4][5]. Antengene is the primary developer of both compounds.

Brand names

Xpovio

Other names

selinexor + onatasertib